In the complex machinery of modern healthcare, the transition from initial treatment to long-term maintenance is often where the most critical gaps in care emerge. For patients within managed care systems, the focus frequently lands on the “entry point”—ensuring a patient gets the right drug or therapy to start. However, a growing concern among clinical pharmacists and policy experts is the “missing measure”: continuation appropriateness in managed care.
Continuation appropriateness refers to the ongoing evaluation of whether a treatment remains necessary, effective, and safe for a patient over time. Whereas initial prescribing is heavily scrutinized through prior authorization and clinical guidelines, the subsequent phase—where patients remain on a therapy for months or years—often lacks the same level of rigorous, systemic oversight. This gap can lead to “therapeutic inertia,” where medications are continued long after their clinical utility has peaked or when a more appropriate alternative has develop into available.
As a physician and journalist, I have observed that the tension between cost-containment and clinical quality is most evident in these long-term maintenance phases. In managed care, where financial incentives are often tied to capitation rates and cost-reduction, the challenge is to ensure that “efficiency” does not come at the cost of periodic clinical re-evaluation.
The Economic Tension in Managed Care Delivery
To understand why continuation appropriateness is often overlooked, one must first gaze at the structural incentives of managed care. Unlike the traditional fee-for-service (FFS) model, where providers are paid for each individual service rendered, managed care organizations (MCOs) typically operate on a capitation basis. This means the state or payer provides a fixed dollar amount per member per month to cover a defined set of services according to the Medicare and Medicaid Payments Advisory Commission (MACPAC).
This shift in financial risk creates a dual-edged sword. On one hand, capitation may reduce the incentive to “overtreat” patients, a common criticism of the FFS model. The pressure to contain costs and the use of defined provider networks can potentially counteract the objective of providing the highest quality of care. When the system is designed to prioritize the initial approval of a service, the “continuation phase” can become a blind spot in governance reviews.
For the clinical pharmacist, this manifests as a discrepancy between what is “approved” and what is “appropriate.” A medication may have been the correct choice three years ago, but without a formal measure for continuation appropriateness, the patient may remain on a regimen that no longer aligns with their current health status or the latest evidence-based guidelines.
Identifying the Gaps in Clinical Governance
Governance reviews in managed care often focus on compliance and initial access. However, a deeper look at clinical pharmacy data suggests that the “missing measure” is the systematic audit of long-term therapy. When a clinical pharmacist reviews a patient’s longitudinal record, they are not just looking for the presence of a drug, but for the evidence that the drug is still working.
The lack of a standardized metric for continuation appropriateness means that many patients are essentially “grandfathered” into treatments. What we have is particularly risky in areas such as:
- Chronic Disease Management: Where guidelines for hypertension or diabetes may evolve, but patient regimens remain static.
- High-Cost Specialty Biologics: Where the financial burden is high, but the clinical efficacy may diminish over time due to the development of antibodies or disease progression.
- Polypharmacy in Geriatrics: Where the addition of new medications often occurs without the removal of outdated ones, increasing the risk of adverse drug interactions.
Without a dedicated measure to track how often treatments are reviewed for appropriateness, MCOs may be meeting their contractual obligations for “access to care” while failing to optimize the “quality of care” over the long term.
The Impact on Patient Outcomes
The goal of any managed care system is to provide appropriate care to avoid expensive hospital stays and emergency department visits as noted by MACPAC. When continuation appropriateness is ignored, the risk of adverse events increases. A patient on an inappropriate long-term medication is more likely to experience side effects or therapeutic failure, which ultimately leads to the very emergency interventions the managed care model seeks to prevent.
the “continuation phase” is where the most significant opportunities for cost-saving and health improvement intersect. By identifying patients who no longer require a specific high-cost therapy, MCOs can reallocate resources toward more effective interventions, creating a “win-win” for both the payer and the patient.
Moving Toward a Standardized Measure of Appropriateness
Addressing the “missing measure” requires a shift in how managed care organizations approach clinical auditing. Rather than viewing prior authorization as a one-time “gatekeeping” event, it must evolve into a continuous cycle of evaluation. This involves integrating clinical pharmacist reviews into the regular governance structure of the MCO.
A robust framework for continuation appropriateness would include:
- Scheduled Re-evaluations: Mandatory clinical reviews at set intervals (e.g., every 6 or 12 months) for high-risk or high-cost therapies.
- Outcome-Based Metrics: Requiring documented evidence of therapeutic benefit (e.g., lab values, functional scores) to justify the continuation of a treatment.
- Deprescribing Protocols: Establishing clear guidelines for when and how to safely taper a patient off a medication that is no longer appropriate.
By implementing these measures, healthcare systems can move away from a “set and forget” mentality and toward a dynamic model of precision medicine. This ensures that the “appropriate care” promised by Medicaid and other managed care entities is not just a starting point, but a constant standard throughout the patient’s journey.
Key Takeaways for Stakeholders
- For Patients: Regularly inquire your provider if your current long-term medications are still the most appropriate choice based on your current health status.
- For Clinicians: Advocate for “deprescribing” as a formal part of the care plan, rather than focusing solely on new prescriptions.
- For MCO Administrators: Integrate “continuation appropriateness” as a Key Performance Indicator (KPI) in clinical governance reviews to improve long-term outcomes and reduce waste.
The conversation surrounding managed care often oscillates between access and cost. However, the real frontier of quality improvement lies in the middle: the ability to ensure that once care begins, it remains appropriate for as long as it is delivered. As the industry evolves, filling this “missing measure” will be essential for achieving true value-based care.
For those tracking healthcare policy, the next critical point of observation will be the evolving regulatory requirements for Medicaid managed care organizations regarding quality improvement initiatives under 42 CFR 438.330. We will continue to monitor how these mandates translate into actual clinical practice.
Do you believe your current healthcare plan does enough to review your long-term medications? Share your experiences in the comments below or share this article to spark a conversation about medication appropriateness.